Market
Eli Lilly Increases Production Capacity for Diabetes and Obesity Medicines by End of 2026?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Eli Lilly's production reports or official statements
Story
Eli Lilly Boosts Wisconsin Plant with $3B Investment, Adding 750 Jobs
Dec 5, 2024, 08:33 PM
Eli Lilly and Co. has announced a significant investment of $3 billion to expand its manufacturing facility in Pleasant Prairie, Wisconsin. The expansion aims to increase production capacity for diabetes and obesity medicines, responding to the soaring demand for these treatments. This move is part of a broader $23 billion investment in global manufacturing since 2020. The expansion is expected to create 750 new jobs and will benefit millions of patients globally by enhancing the supply of Lilly's weight-loss and diabetes drugs.
View original story
Similar markets
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
AstraZeneca • 25%
Eli Lilly > 60% • 25%
Novo Nordisk 40-60% • 25%
Novo Nordisk > 60% • 25%
Eli Lilly 40-60% • 25%
Brain disorders • 25%
Heart disease • 25%
Stroke • 25%
Kidney disease • 25%